On September 19, 2022, Pierre Lorenzo notified the board of directors of Tempest Therapeutics, Inc. of his decision to resign as the Company's Corporate Controller, Treasurer, Principal Accounting Officer and Secretary, effective September 30, 2022. Mr. Lorenzo's resignation was not due to any disagreement with the Company on any matter relating to the Company's operations, policies, or practices. On September 21, 2022, the Board approved the promotion and appointment of Justin Trojanowski, as the Company's Corporate Controller, Treasurer and Principal Accounting Officer, effective September 30, 2022.

The Board also appointed Nicholas Maestas, the Company's Vice President, Strategy and Finance, as the Company's Secretary, effective September 30, 2022. Justin Trojanowski, age 34, has served as the Company's Director, Finance and Assistant Controller since June 2022. Prior to joining the Company, Mr. Trojanowski served as Associate Director, Accounting at Nektar Therapeutics, a biopharmaceutical company, from June 2019 to June 2022.

Prior to Nektar, Mr. Trojanowski served as Senior Manager, Accounting at Immune Design, a late-stage oncology company that was acquired by Merck in 2019, from June 2018 to May 2019. Prior to Immune Design, Mr. Trojanowski worked at Ernst & Young, Global Limited, a multinational audit and professional services company, from September 2012 to May 2018, most recently as an Assurance Manager. Mr. Trojanowski received his B.S. in Accountancy from Providence College and an M.B.A. in Accountancy from Providence College, and is a Certified Public Accountant.